Heart failure with preserved ejection fraction
Conditions
Interventions
Beta-blocker withdrawal or dose reduction
Sponsors
Obokata Masaru
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Age equal to or more than 20 years old 2) Patients with established HFpEF or subjects who are suspected of HFpEF 3) Subjects who are treated with a pre-specified minimum dose of beta-blockers 5) Subjects who are able to keep cycle ergometry exercise (0 watts) for more than 30 seconds 6) Patients who give written consent to participate in this study
Exclusion criteria
Exclusion criteria: 1) Patients with mimic HFpEF: More than mild aortic or mitral valve stenosis, more than moderate aortic or mitral valve regurgitation, history of left ventricular ejection fraction less than 40%, non-group II pulmonary hypertension, hypertrophic cardiomyopathy (except for apical hypertrophic cardiomyopathy), cardiac sarcoidosis, constrictive pericardititis 2) Patients with comorbidities contraindicated for exercise testing: acute decompensated heart failure, acute coronary syndrome, severe coronary artery disease 3) Patients who are expected to have disadvantages in discontinuing beta-blockers: History of old myocardial infarction, presence of obvious myocardial ischemia, appearance of new wall motion abnormality during exercise, history of hospitalization due to tachyarrhythmia within 6 months, Basedow's disease 4) Patients who cannot exercise their legs due to abnormalities in joints, muscles, etc. 4) Patients who are judged to be unsuitable for th e study by the investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in peak oxygen consumption during exercise stress echocardiography from baseline to four-weeks after the intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| *Changes in the following parameters from baseline to four-weeks after the intervention will be assessed: Heart rate during peak exercise Cardiac output during peak exercise Mitral s' during peak exercise GLS during peak exercise VE/VCO2 slope NT-proBNP levels *The following prognostic data will be also assessed: Time to first heart failure hospitalization Time to all-cause mortality Time to cardiac death Time to first heart failure hospitalization or all-cause mortality Time to first heart failure hospitalization or cardiac death | — |
Contacts
Public ContactMasaru Obokata
Gunma University Hospital
Outcome results
None listed